» Articles » PMID: 26834831

Whole Genome Sequencing Shows Sleeping Sickness Relapse is Due to Parasite Regrowth and Not Reinfection

Overview
Journal Evol Appl
Specialty Biology
Date 2016 Feb 3
PMID 26834831
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The trypanosome Trypanosoma brucei gambiense (Tbg) is a cause of human African trypanosomiasis (HAT) endemic to many parts of sub-Saharan Africa. The disease is almost invariably fatal if untreated and there is no vaccine, which makes monitoring and managing drug resistance highly relevant. A recent study of HAT cases from the Democratic Republic of the Congo reported a high incidence of relapses in patients treated with melarsoprol. Of the 19 Tbg strains isolated from patients enrolled in this study, four pairs were obtained from the same patient before treatment and after relapse. We used whole genome sequencing to investigate whether these patients were infected with a new strain, or if the original strain had regrown to pathogenic levels. Clustering analysis of 5938 single nucleotide polymorphisms supports the hypothesis of regrowth of the original strain, as we found that strains isolated before and after treatment from the same patient were more similar to each other than to other isolates. We also identified 23 novel genes that could affect melarsoprol sensitivity, representing a promising new set of targets for future functional studies. This work exemplifies the utility of using evolutionary approaches to provide novel insights and tools for disease control.

Citing Articles

Vector-borne Trypanosoma brucei parasites develop in artificial human skin and persist as skin tissue forms.

Reuter C, Hauf L, Imdahl F, Sen R, Vafadarnejad E, Fey P Nat Commun. 2023; 14(1):7660.

PMID: 37996412 PMC: 10667367. DOI: 10.1038/s41467-023-43437-2.


VSGs Expressed during Natural T. b. gambiense Infection Exhibit Extensive Sequence Divergence and a Subspecies-Specific Bias towards Type B N-Terminal Domains.

So J, Sudlow S, Sayeed A, Grudda T, Deborggraeve S, Ngoyi D mBio. 2022; 13(6):e0255322.

PMID: 36354333 PMC: 9765701. DOI: 10.1128/mbio.02553-22.


Systematic Review and Meta-Analysis on Human African Trypanocide Resistance.

Kasozi K, MacLeod E, Welburn S Pathogens. 2022; 11(10).

PMID: 36297157 PMC: 9612373. DOI: 10.3390/pathogens11101100.


Paving the Way: Contributions of Big Data to Apicomplexan and Kinetoplastid Research.

Kent R, Briggs E, Colon B, Alvarez C, Silva Pereira S, De Niz M Front Cell Infect Microbiol. 2022; 12:900878.

PMID: 35734575 PMC: 9207352. DOI: 10.3389/fcimb.2022.900878.


Two-Year Follow-Up of Serology after Successful Treatment of Human African Trypanosomiasis: Results of Four Different Sero-Diagnostic Tests.

Inocencio da Luz R, Tablado Alonso S, Buscher P, Verle P, De Weggheleire A, Ngoyi D Diagnostics (Basel). 2022; 12(2).

PMID: 35204337 PMC: 8871350. DOI: 10.3390/diagnostics12020246.


References
1.
Maser P, Sutterlin C, Kralli A, Kaminsky R . A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science. 1999; 285(5425):242-4. DOI: 10.1126/science.285.5425.242. View

2.
MacLeod A, Turner C, Tait A . A high level of mixed Trypanosoma brucei infections in tsetse flies detected by three hypervariable minisatellites. Mol Biochem Parasitol. 1999; 102(2):237-48. DOI: 10.1016/s0166-6851(99)00101-2. View

3.
Stanghellini A, Josenando T . The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001; 6(5):330-4. DOI: 10.1046/j.1365-3156.2001.00724.x. View

4.
Moore A, Richer M . Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health. 2001; 6(5):342-7. DOI: 10.1046/j.1365-3156.2001.00714.x. View

5.
Blum J, Nkunku S, Burri C . Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health. 2001; 6(5):390-400. DOI: 10.1046/j.1365-3156.2001.00710.x. View